Explore the vast range of titles available.

BackgroundMail order pharmacy (MOP) use has been linked to improved medication adherence and health outcomes among patients with diabetes. However, no large-scale intervention studies have assessed the effect of encouraging MOP use on medication adherence.ObjectiveTo assess an intervention to encourage MOP services to increase its use and medication adherence.DesignRandomized encouragement trial.Patients63,012 diabetes patients from three health care systems: Kaiser Permanente Northern California (KPNC), Kaiser Permanente Hawaii (KPHI), and Harvard Pilgrim Health Care (HPHC) who were poorly adherent to at least one class of cardiometabolic medications and had not used MOP in the prior 12 months.InterventionPatients were randomized to receive either usual care (control arm) or outreach encouraging MOP use consisting of a mailed letter, secure email message, and automated telephone call outlining the potential benefits of MOP use (intervention arm). HPHC intervention patients received the letter only.MeasurementsWe compared the percentages of patients that began using MOP and that became adherent to cardiometabolic medication classes during a 12-month follow-up period. We also conducted a race/ethnicity-stratified analysis.ResultsDuring follow-up, 10.6% of intervention patients began using MOP vs. 9.3% of controls (p < 0.01); the percent of cardiometabolic medication delivered via mail was 42.1% vs. 39.8% (p < 0.01). Metformin adherence improved in the intervention arm relative to control at the two KP sites (52% vs. 49%, p < 0.01). Stratified analyses suggested a significant positive effect of the intervention in White (RR: 1.12, 95% CI: 1.03, 1.22) and Asian (RR: 1.30, 95% CI: 1.17, 1.45) patients.ConclusionThis pragmatic trial showed that simple outreach to encourage MOP modestly increased its use and improved adherence measured by refills to a key class of diabetes medications in some settings. Given its minimal cost, clinicians and health systems should consider outreach interventions to actively promote MOP use among diabetes patients.Trial RegistrationClinicalTrials.gov registration number: NCT02621476

Postpartum hemorrhage (PPH) is a leading cause of obstetric morbidity. There is limited understanding of patients' knowledge about blood loss at delivery, PPH, and PPH-related morbidities, including transfusion and anemia. We surveyed 100 healthy postpartum patients who underwent vaginal or cesarean delivery about blood loss, and whether they received information about transfusion and peripartum hemoglobin (Hb) testing. Responses were compared between women undergoing vaginal delivery vs. cesarean delivery; P < 0.05 considered as statistically significant. In our cohort, 49 women underwent vaginal delivery and 51 women underwent cesarean delivery. Only 29 (29%) of women provided blood loss estimates for their delivery. Women who underwent cesarean delivery were more likely to receive clear information about transfusion therapy than those undergoing vaginal delivery (43.1% vs. 20.4% respectively; P = 0.04). Women who underwent vaginal delivery were more likely to receive results of postpartum Hb tests compared to those undergoing cesarean delivery (49% vs. 29.4%; P = 0.02). Our findings suggest that women are poorly informed about the magnitude of blood loss at delivery. Hematologic information given to patients varies according to mode of delivery. Further research is needed to better understand the clinical implications of patients' knowledge gaps about PPH, transfusion and postpartum anemia.

Cytarabine (Ara-C) and Daunorubicin (Dnr) forms the backbone of acute myeloid leukemia (AML) therapy. Drug resistance and toxic side effects pose a major threat to treatment success and hence alternate less toxic therapies are warranted. NF-E2 related factor-2 (Nrf2), a master regulator of antioxidant response is implicated in chemoresistance in solid tumors. However, little is known about the role of Nrf2 in AML chemoresistance and the effect of pharmacological inhibitor brusatol in modulating this resistance. Primary AML samples with high ex-vivo IC50 to Ara-C, ATO, Dnr had significantly high NRF2 RNA expression. Gene-specific knockdown of NRF2 improved sensitivity to these drugs in resistant AML cell lines by decreasing the expression of downstream antioxidant targets of Nrf2 by compromising the cell's ability to scavenge the ROS. Treatment with brusatol, a pharmacological inhibitor of Nrf2, improved sensitivity to Ara-C, ATO, and Dnr and reduced colony formation capacity. AML cell lines stably overexpressing NRF2 showed increased resistance to ATO, Dnr and Ara-C and increased expression of downstream targets. This study demonstrates that Nrf2 could be an ideal druggable target in AML, more so to the drugs that function through ROS, suggesting the possibility of using Nrf2 inhibitors in combination with chemotherapeutic agents to modulate drug resistance in AML.

Rare earth iron garnets are scientifically significant because the versatility of cation substitution in various geometrical locations results in adjustable and varied characteristics for magnetic devices and optoelectronics applications. In a rare earth iron garnet, such as Dy 3 Fe 5 O 12 , electronic states are very sensitive to substitutional effects. The objective of the current research was to synthesize garnet type-Dy 3 Fe 5 O 12 compound and optimal parameters of the hydrothermal method were determined. We present here a detailed experimental investigation of electronic states and their distribution across the sites in Dy 3 Ni x Fe 5-x O 12 compounds through X-ray photoelectron spectroscopy. Scanning electron micrographs demonstrated that nanoparticles with whiskers in morphology with the existence in soft agglomeration. The impact of nickel replacing the cubic formation of garnets was explored using X-ray diffraction and Fourier transform infrared spectroscopy. In addition, the Fe: Ni ratio affects the magnetization and anisotropy of Dy 3 Ni x Fe 5-x O 12 . This indicates that the magnetism of rare-earth iron garnet can be greatly tuned by customizing its composition leading to use in a wide range of applications. Graphical Abstract

The research investigated how the replacement of iron (Fe) with copper (Cu) ions affects the formation of crystals and magnetic properties in Dy 3 Fe 5-x Cu x O 12 (with x values of 0.0, 0.2, 0.4, and 0.6) created using the hydrothermal method. X-ray diffraction analysis confirmed that all the samples consisted of garnet-type-cubic crystals and exhibited a nanocrystalline nature. The grain size (71.01–65.51 nm) and lattice parameter (12.38–12.31 Å) decreased as the level of copper doping increased up to 0.06, indicating a significant substitution of copper in the iron sites. Fourier-transform infrared spectroscopy revealed distinct vibrational bands characteristic of DyIG and confirmed the replacement in octahedral and tetrahedral sites. Scanning electron microscopy analysis showed the presence of nanometer-sized grains with a whisker-like shape. X-ray photoelectron spectroscopy confirmed the valence states of Dy, Cu, and Fe as Dy 3+ , Cu 3+ , Cu 2+ , Fe 3+ , and Fe 2+ . The vibrating sample magnetometer demonstrated that the substitution of Fe with Cu in the A and D-sites resulted in a reduction of the saturation magnetization (Ms) from 14.41 to 7.46 emu/g within the range of 0.000 ≤ x ≤ 0.060. Changes in coercive fields at different dopant concentrations were attributed to variations in the magnetocrystalline anisotropy constant.

Purpose of ReviewThis review aims to investigate the blood pressure (BP)-lowering effects of emerging drugs developed to treat diabetic kidney disease and heart failure (HF). We summarize the potential pathophysiological mechanisms responsible for mitigating hypertensive target organ damage and evaluating the available clinical data on these newer drugs.Recent FindingsNonsteroidal dihydropyridine-based mineralocorticoid receptor antagonists (MRAs), dual angiotensin II receptor-neprilysin inhibitors (valsartan with sacubitril), sodium-glucose cotransporter 2 inhibitors (SGLT2i), and soluble guanylate cyclase stimulators are new classes of chemical agents that have distinct mechanisms of action and have been shown to be effective for the treatment of cardiovascular (CV) disease (CVD), HF, and type 2 diabetes mellitus (T2D). These drugs can be used either alone or in combination with other antihypertensive and CV drugs. Among these, SGLT2i and valsartan with sacubitril offer new avenues to reduce CVD mortality. SGLT2i have a mild-to-moderate effect on BP lowering with a favorable effect on CV and renal hemodynamics and have been shown to produce a significant reduction in the incidence of major adverse CVD events (as monotherapy or add-on therapy) compared with controls (placebo or non-SGLT2i treatment). Most of the participants in these studies had hypertension (HTN) at baseline and were receiving antihypertensive therapy, including renin-angiotensin system blockers. The combination of valsartan with sacubitril also lowers BP in the short term and has demonstrated a striking reduction in CVD mortality and morbidity in HF patients with a reduced left ventricular ejection fraction. If widely adopted, these novel therapeutic agents hold significant promise for reducing the public health burden posed by HTN and CVD.SummaryBased on the results of several clinical trials and considering the high prevalence of HTN and T2D, these new classes of agents have emerged as powerful therapeutic tools in managing and lowering the BP of patients with diabetic kidney disease and HF.

Objective: This study aims to test how fisetin and dapagliflozin—alone and combined—affect reproductive cycles, blood markers, hormones, oxidative stress, and tissue changes in DHEA-induced PCOS rats. Materials and methods: This study used 30 female rats split into five groups of six animals each: normal controls, PCOS disease controls, fisetin treatment, dapagliflozin treatment, and combination treatment. PCOS was created by giving the rats DHEA injections under the skin for 21 days, followed by 28 days of treatment. The researchers measured body weight, reproductive cycles, organ weights, hormone levels (LH, FSH, testosterone, insulin), cholesterol profiles, oxidative stress markers (MDA, SOD), inflammation markers (TNF-α, IL-6), and examined tissue samples under a microscope. Results: PCOS induction in rats caused estrous cycle disruption (shown through vaginal cytology), weight gain, elevated LH/testosterone/insulin levels, and compromised antioxidant status. Individual fisetin and dapagliflozin treatments significantly ameliorated these abnormalities, but their combination demonstrated the most comprehensive therapeutic benefits, effectively restoring reproductive cycles, hormonal balance, and metabolic parameters while reducing oxidative damage. Conclusion: Fisetin and dapagliflozin, particularly when used together, helped reduce PCOS-related problems by fighting inflammation, protecting against cellular damage, and improving insulin function. This likely works by influencing the PI3K/AKT cellular signaling pathway.

Background Interest in phage therapy has grown over the past decade due to the rapid emergence of antibiotic resistance in bacterial pathogens. However, the use of bacteriophages for therapeutic purposes has raised concerns over the potential for immune response, rapid toxin release by the lytic action of phages, and difficulty in dose determination in clinical situations. A phage that kills the target cell but is incapable of host cell lysis would alleviate these concerns without compromising efficacy. Results We developed a recombinant lysis-deficient Staphylococcus aureus phage P954, in which the endolysin gene was rendered nonfunctional by insertional inactivation. P954, a temperate phage, was lysogenized in S. aureus strain RN4220. The native endolysin gene on the prophage was replaced with an endolysin gene disrupted by the chloramphenicol acetyl transferase ( cat ) gene through homologous recombination using a plasmid construct. Lysogens carrying the recombinant phage were detected by growth in presence of chloramphenicol. Induction of the recombinant prophage did not result in host cell lysis, and the phage progeny were released by cell lysis with glass beads. The recombinant phage retained the endolysin-deficient genotype and formed plaques only when endolysin was supplemented. The host range of the recombinant phage was the same as that of the parent phage. To test the in vivo efficacy of the recombinant endolysin-deficient phage, immunocompromised mice were challenged with pathogenic S. aureus at a dose that results in 80% mortality (LD 80 ). Treatment with the endolysin-deficient phage rescued mice from the fatal S. aureus infection. Conclusions A recombinant endolysin-deficient staphylococcal phage has been developed that is lethal to methicillin-resistant S. aureus without causing bacterial cell lysis. The phage was able to multiply in lytic mode utilizing a heterologous endolysin expressed from a plasmid in the propagation host. The recombinant phage effectively rescued mice from fatal S. aureus infection. To our knowledge this is the first report of a lysis-deficient staphylococcal phage.

Achieving early molecular response (EMR) has been shown to be associated with better event free survival in patients with chronic phase chronic myeloid leukemia (CP-CML) on Imatinib therapy. We prospectively evaluated the factors influencing the 2-year failure free survival (FFS) and EMR to imatinib therapy in these patients including day29 plasma Imatinib levels, genetic variants and the gene expression of target genes in imatinib transport and biotransformation. Patients with low and intermediate Sokal score had better 2-year FFS compared to those with high Sokal Score (p = 0.02). Patients carrying ABCB1-C1236T variants had high day29 plasma imatinib levels (P = 0.005), increased EMR at 3 months (P = 0.044) and a better 2 year FFS (P = 0.003) when compared to those with wild type genotype. This translates to patients with lower ABCB1 mRNA expression having a significantly higher intracellular imatinib levels (P = 0.029). Higher day29 plasma imatinib levels was found to be strongly associated with patients achieving EMR at 3 months (P = 0.022), MMR at 12 months (P = 0.041) which essentially resulted in better 2-year FFS (p = 0.05). Also, patients who achieved EMR at 3 months, 6 months and MMR at 12 months had better FFS when compared to those who did not. This study suggests the incorporation of these variables in to the imatinib dosing algorithm as predictive biomarkers of response to Imatinib therapy.

Objective: This study aims to test how fisetin and dapagliflozin—alone and combined—affect reproductive cycles, blood markers, hormones, oxidative stress, and tissue changes in DHEA-induced PCOS rats. Materials and methods: This study used 30 female rats split into five groups of six animals each: normal controls, PCOS disease controls, fisetin treatment, dapagliflozin treatment, and combination treatment. PCOS was created by giving the rats DHEA injections under the skin for 21 days, followed by 28 days of treatment. The researchers measured body weight, reproductive cycles, organ weights, hormone levels (LH, FSH, testosterone, insulin), cholesterol profiles, oxidative stress markers (MDA, SOD), inflammation markers (TNF-α, IL-6), and examined tissue samples under a microscope. Results: PCOS induction in rats caused estrous cycle disruption (shown through vaginal cytology), weight gain, elevated LH/testosterone/insulin levels, and compromised antioxidant status. Individual fisetin and dapagliflozin treatments significantly ameliorated these abnormalities, but their combination demonstrated the most comprehensive therapeutic benefits, effectively restoring reproductive cycles, hormonal balance, and metabolic parameters while reducing oxidative damage. Conclusion: Fisetin and dapagliflozin, particularly when used together, helped reduce PCOS-related problems by fighting inflammation, protecting against cellular damage, and improving insulin function. This likely works by influencing the PI3K/AKT cellular signaling pathway.